Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?

Key Takeaways Mirum's revenues hinge on Livmarli, which generated $253.6M in the first nine months of 2025.MIRM expects continued Livmarli growth as increasing global adoption supports demand.Cholbam and Ctexli sales also rose, adding to Mirum's expanding rare-disease drug portfolio.Mirum Pharmaceuticals’ (MIRM) revenue base is largely supported by its lead product, Livmarli (maralixibat), which has been witnessing steady sales uptake since its launch. The drug remains a key top-line driver for the company. ...